Drugs / lufotrelvir
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05050682 | Oct → Dec 2021 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04627532 | Oct → Dec 2020 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04535167 | Sep 2020 → Jun 2021 | viral infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT05780541 | Sep 2021 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 3 | NCT04501978 | Aug 2020 → Apr 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lufotrelvir | “PF-07304814-the prodrug (lufotrelvir) and its active moiety (PF-00835231)-is a potent inhibitor of the SARS-CoV-2 3CL protease.” PMID 37559753 ↗ Jul 20231“PF-07304814 (lufotrelvir) is the phosphate prodrug of PF-00835231” PMID 36285536 ↗ Oct 2022 |
| Known as | PF-07304814 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04501978 ↗ |
| Action | Inhibit | “is a potent inhibitor of the SARS-CoV-2 3CL protease.” PMID 37559753 ↗ Jul 2023 |
| Modality | Small molecule | — CHEMBL4802214 ↗ |
| Route | Intravenous | “Administered as a constant rate intravenous infusion.” NCT04501978 ↗ |